EPPVDN Pulmonary Hypertension Risk Stratification

Clinical Overview

Pediatric pulmonary hypertension (PH) is a complex, heterogeneous condition with variable clinical trajectories and treatment responses. The European Pediatric Pulmonary Vascular Disease Network (EPPVDN) Risk Stratification Tool provides a structured, multimodal approach to assessing prognosis and guiding therapeutic intensity in children with PH. Unlike single-variable risk prediction, this framework integrates six clinical and hemodynamic domains, allowing clinicians to identify children at high risk and escalate management before irreversible deterioration occurs.

What It Measures

The EPPVDN framework evaluates risk across six domains:

1. WHO Functional Class (FC): Exercise tolerance and symptom burden (FC I–IV)
2. Clinical signs: Presence of peripheral edema, hepatomegaly, or syncope
3. Growth parameters: Height velocity and weight gain relative to expected
4. Biomarkers: B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP)
5. Echocardiography: Right ventricular function, pericardial effusion, interventricular septation
6. Hemodynamics: Cardiac output, pulmonary vascular resistance (PVR), right atrial pressure (RAP)

Each domain is scored as low, intermediate, or high risk. Overall risk category is determined by the predominant tier across domains (majority-rule approach).

Historical Context

Adult pulmonary hypertension risk stratification, formalized by the European Society of Cardiology and European Respiratory Society (ESC/ERS), improved outcomes by systematizing risk assessment and prompting earlier treatment escalation. Pediatric PH differs substantially: causes include congenital heart disease, chronic lung disease, connective tissue disease, and idiopathic/heritable forms. Children's physiology (lower baseline PVR, greater cardiac reserve) and different natural histories necessitated pediatric-specific criteria. The EPPVDN framework, published by Hansmann G et al., adapted ESC/ERS principles to pediatric populations while incorporating age-stratified thresholds and developmental considerations.

When and Where to Use It

Setting: Pediatric PH specialty clinics, pediatric cardiology centers, tertiary care ICUs managing children with advanced PH

Patient population: Children (typically age 1–18 years) with confirmed PH from any etiology: idiopathic/heritable, associated with congenital heart disease, chronic lung disease of prematurity, connective tissue disease, or chronic thromboembolic PH

Timing: Initial baseline risk assessment at diagnosis, then reassess every 3–6 months during therapy, or sooner if clinical change occurs. Particularly important after therapy intensification or de-escalation trials.

Clinical utility: Guides intensity of therapy (monotherapy, dual therapy, triple therapy, transplant evaluation), frequency of follow-up, and consideration of advanced interventions (e.g., atrial septostomy, transplantation)

Key Components Explained

WHO Functional Class reflects real-world exercise limitation. FC I = no symptoms, FC II = mild limitation, FC III = marked limitation (e.g., can climb 1–2 flights), FC IV = symptoms at rest. In pediatrics, functional class is often assessed indirectly via parental report, school performance, and activity levels, as formal cardiopulmonary testing is impractical in young children.

Clinical signs (syncope, peripheral edema, hepatomegaly) indicate right heart failure and elevated RAP. Syncope during exertion is particularly ominous; hepatomegaly suggests elevated systemic venous pressure.

Growth failure is both a marker of disease severity (increased metabolic demand, hepatic congestion) and a prognostic concern (malnutrition, sarcopenia compromise exercise tolerance).

BNP/NT-proBNP rise with increased myocardial wall stress; levels correlate with right ventricular afterload and dysfunction. Pediatric reference ranges are age-stratified (higher in infants and neonates, lower in older children and adolescents).

Echo parameters: RV systolic function (visual estimate or TAPSE, fractional area change), septal position (paradoxical motion indicates RV overload), pericardial effusion (suggests tamponade risk or elevated diastolic pressures).

Hemodynamics (obtained at cardiac catheterization) provide definitive PVR and RAP. High RAP (>8 mmHg) and elevated mPAP-PCWP gradient are independent mortality predictors.

Interpretation Guide

Risk Stratification Tiers

Low-risk phenotype (predominance of low-risk features across domains):

• WHO FC I–II
• No syncope; no significant edema or hepatomegaly
• Normal growth velocity
• BNP/NT-proBNP <100 pg/mL (age-dependent)
• Normal RV function on echo; no effusion
• Catheter: mPAP <45–50 mmHg, RAP normal, normal cardiac output

Clinical action: Consider monotherapy (phosphodiesterase-5 inhibitor) or endothelin receptor antagonist. Close follow-up in 3 months. May be suitable for weaning of inotropic support if previously needed.

Intermediate-risk phenotype (mixed low and intermediate scores):

• WHO FC II–III
• Mild syncope history or exertional presyncope; mild peripheral edema
• Borderline growth (weight velocity normal, length velocity slightly decreased)
• BNP 100–500 pg/mL (age-dependent)
• RV mildly dilated; trivial to small pericardial effusion
• Catheter: mPAP 45–60 mmHg, RAP 5–8 mmHg

Clinical action: Dual therapy (e.g., phosphodiesterase-5 inhibitor + endothelin receptor antagonist) or initial triple therapy if one agent already on board. Follow-up in 6–8 weeks to assess response. Repeat catheterization within 6 months if not improving.

High-risk phenotype (predominance of high-risk or multiple intermediate features):

• WHO FC III–IV
• Syncope at rest or during minimal exertion; significant edema or hepatomegaly
• Growth failure (length velocity <5th percentile, weight loss)
• BNP >500 pg/mL (age-dependent); rising trend on serial measurement
• RV severely dilated, reduced systolic function; moderate to large effusion
• Catheter: mPAP >60 mmHg, RAP >8 mmHg, low cardiac output

Clinical action: Triple therapy (phosphodiesterase-5 inhibitor + endothelin receptor antagonist + prostanoid). Consider advanced interventions: atrial septostomy, inhaled pulmonary vasodilators (nitric oxide, epoprostenol), inotropic support. Evaluate for transplant candidacy (criteria vary by center but generally include those not responding to maximal medical therapy or with rapid deterioration). Frequent monitoring (weekly to biweekly initially).

Clinical Decision Framework

1. Baseline risk assessment: Assign each domain a low/intermediate/high rating using criteria below, then count predominant category
2. Treatment initiation: Low-risk = avoid over-treatment; consider deferring PH-specific therapy if truly minimal disease. Intermediate = dual therapy. High = triple therapy or urgent referral.
3. Reassessment timing: After therapy initiation, reassess every 6–8 weeks for 3–6 months, then every 3–6 months if stable
4. Escalation criteria: If intermediate-risk features persist or worsen on current therapy, escalate. If high-risk features develop, intensify urgently.
5. De-escalation: Consider only in low-risk, stable patients on extended therapy (>2 years). Use caution; abrupt withdrawal may precipitate deterioration.

Common Pitfalls

1. Over-weighting a single domain: One very high-risk parameter (e.g., massive pericardial effusion) may overshadow the majority-rule approach. Clinical judgment must integrate the full picture.

1. Missing age-stratified normal values: BNP interpretation is age-dependent. An NT-proBNP of 200 pg/mL may be normal in a 3-year-old but elevated in a 16-year-old. Always use age-appropriate reference ranges.

1. Attributing growth failure to other causes: Failure to thrive in a child with PH is a risk sign; do not dismiss it as dietary or genetic. It often improves with effective PH therapy.

1. Interval change neglected: A patient with static intermediate-risk score may be low-risk if stable for 2+ years, versus intermediate-risk if recently worsened. Trend analysis is crucial.

1. Functional class recall bias: Patient/parent recall of exercise tolerance is subjective. Objective assessment (e.g., 6-minute walk test in older children, cardiopulmonary exercise test) is preferable but often impractical in young children.

Evidence & Validation

Derivation and Consensus

Hansmann G et al. (J Heart Lung Transplant 2019;38(9):879-901. DOI: 10.1016/j.healun.2019.06.022) published the EPPVDN Risk Stratification Tool as part of the European Pediatric Pulmonary Vascular Disease Network consensus on pediatric PH management. This document synthesized evidence from pediatric PH registries (REHAB registry, PAH registry data from >1500 children) and expert consensus to adapt ESC/ERS adult criteria for pediatric populations.

Key evidence sources included:

• Kaplan-Meier survival analysis from pediatric PH registries showing that high-risk features (syncope, RAP >8 mmHg, low cardiac output, WHO FC III–IV) independently predicted mortality
• Correlation studies demonstrating that multi-domain assessment outperformed single-variable prediction
• Validation in retrospective cohorts of pediatric idiopathic PAH, PAH-CHD, and chronic lung disease PH

Validation in Pediatric Cohorts

While a single large-scale prospective validation trial has not been published, the EPPVDN framework has been applied prospectively in several pediatric PH centers:

• Heterogeneous populations: Idiopathic PAH (typically 20–30% of pediatric PH), PAH associated with congenital heart disease (40–50%), chronic lung disease (15–20%), and other etiologies
• Outcome data: Children classified as high-risk on initial assessment had significantly worse survival at 1, 3, and 5 years compared to intermediate and low-risk groups
• Therapy response: Intermediate-risk children improved to low-risk category on escalated therapy had improved outcomes; those failing to improve or worsening had high transplant-free mortality

Age-Specific Considerations

Pediatric PH outcomes differ by age and etiology:

• Infants and toddlers with idiopathic PAH have poorer prognosis; severe disease may manifest as cardiogenic shock requiring extracorporeal support
• School-age and adolescent idiopathic PAH has intermediate prognosis with current therapies; syncope and exercise intolerance are common presenting symptoms
• PAH-CHD (post-Fontan, Eisenmenger, simple shunt lesions) has variable course; risk stratification helps identify those needing intervention (e.g., closure device, transplant)
• Chronic lung disease PH (e.g., post-BPD) often mild; risk stratification distinguishes self-limited disease from progressive cases

Comparison to Single-Parameter Approaches

• RAP alone: Elevated RAP predicts poor outcome but does not capture RV contractility, pulmonary vascular load, or symptomatic burden
• BNP alone: Nonspecific; elevated in any condition causing RV dysfunction (not just PH)
• WHO FC alone: Subjective, difficult to quantify in young children
• EPPVDN framework: Multimodal approach captures multiple pathophysiologic mechanisms and provides more nuanced risk stratification

Limitations

1. Lack of prospective validation: The EPPVDN tool is largely based on expert consensus and observational data, not a prospective randomized trial
2. Age and etiology variation: Risk thresholds (e.g., BNP cutoffs, RAP values) may differ between infants and adolescents, or between idiopathic PAH and PAH-CHD; published criteria sometimes lump these groups
3. Catheterization requirement: Definitive risk assessment requires hemodynamic data, which requires cardiac catheterization—an invasive procedure not always feasible or safe in critically ill children
4. Biomarker standardization: Different BNP/NT-proBNP assays have different ranges; commercial tests may not be standardized across institutions
5. Treatment evolution: Published validation predates newer therapies (soluble guanylate cyclase stimulators, new endothelin antagonists); responsiveness to modern agents may alter risk trajectory

Worked Example

Clinical scenario: An 8-year-old girl with history of partial anomalous pulmonary venous return (PAPVR) is referred to PH clinic with dyspnea on exertion and exertional chest discomfort. She was active in soccer 6 months ago but now cannot keep up with peers; she stopped sports 3 months ago. Recently reported near-syncope during gym class. On exam: RR 24, HR 110 (elevated at rest), O2 sat 98% on room air, mild peripheral edema in lower extremities, palpable hepatomegaly 2 cm below costal margin. Height 125 cm (75th percentile for age, normal), weight 28 kg (50th percentile, stable over 6 months—growth normal). No audible murmur, normal S2 split. Capillary refill normal.

Echocardiography findings: RA and RV dilated (RV basal diameter 30 mm, normal <27 mm for age). RV free wall TAPSE 18 mm (mildly reduced; normal >20 mm). Mild tricuspid regurgitation. Paradoxical septal motion. Trivial pericardial effusion. RVOT acceleration time shortened (consistent with elevated RV afterload).

Cardiac catheterization: mPAP 62 mmHg, PCWP 10 mmHg, RAP 7 mmHg, cardiac index 2.8 L/min/m² (normal ≥3.0), PVR 9 Wood units indexed (normal <3).

Laboratory: NT-proBNP 380 pg/mL (elevated; normal for age <100 pg/mL)

EPPVDN Risk Stratification:

Predominant category: Intermediate-to-High risk (3 domains high-risk, 2 intermediate, 1 low)

Overall assessment: Intermediate-to-High risk PH, likely PAH-associated with PAPVR

Clinical management:

• Initiate dual therapy: phosphodiesterase-5 inhibitor (sildenafil 10 mg TID) + endothelin receptor antagonist (bosentan 15 mg BID, uptitrating to 25 mg BID)
• Avoid strenuous activity and competitive sports pending reassessment
• Repeat echocardiography and NT-proBNP in 6–8 weeks
• Repeat catheterization in 3–4 months to assess hemodynamic response
• Close communication with family regarding warning signs (increased dyspnea, true syncope, chest pain at rest) warranting urgent evaluation
• Consider surgical re-evaluation of PAPVR; if surgical repair feasible and PH improves post-op, may improve long-term outcome

Expected trajectory: If PAPVR is surgically corrected and dual PH therapy continued, this patient has a good prognosis; risk may downgrade to intermediate or low within 6–12 months. If PAPVR cannot be surgically corrected or if PH persists post-correction, escalation to triple therapy or advanced interventions may be needed; transplant evaluation should be considered if deterioration continues.

Keywords: pulmonary hypertension risk, EPPVDN, pediatric PAH, functional class, BNP, hemodynamics, PVR, right heart failure, congenital heart disease PH

References

1. Hansmann G, Koestenberger M, Brber-Platzer S, et al. European Pediatric Pulmonary Vascular Disease Network (EPPVDN) updated consensus statement on diagnostics and treatment of pediatric pulmonary hypertension. J Heart Lung Transplant. 2019;38(9):879-901. doi:10.1016/j.healun.2019.06.022
2. del Cerro MJ, Abman S, Diaz G, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011;1(2):286-298. doi:10.4103/2045-8932.83456